| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 147 |
| 1 | METHOTREXATE SODIUM | 135 |
| 2 | INFLIXIMAB | 134 |
| 3 | RITUXIMAB | 122 |
| 4 | SULFASALAZINE | 118 |
| 5 | METHOTREXATE | 117 |
| 6 | TOCILIZUMAB | 117 |
| 7 | ABATACEPT | 113 |
| 8 | ETANERCEPT | 113 |
| 9 | LEFLUNOMIDE | 112 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPINEPHRINE HYDROCHLORIDE | 9 | 0.0190 |
| 1 | TETRAHYDROZOLINE HYDROCHLORIDE | 5 | 0.0170 |
| 2 | PIRTOBRUTINIB | 8 | 0.0082 |
| 3 | ALBENDAZOLE | 8 | 0.0042 |
| 4 | MINERAL OIL | 6 | 0.0040 |
| 5 | ACETAMINOPHEN AND DIPHENHYDRAMINE HCL | 12 | 0.0036 |
| 6 | DICLOFENAC POTASSIUM TABLETS | 27 | 0.0031 |
| 7 | DEXCHLORPHENIRAMINE MALEATE | 3 | 0.0030 |
| 8 | ACETAMINOPHEN, DEXTROMETHORPHAN HBR | 12 | 0.0029 |
| 9 | ERGOCALCIFEROL | 75 | 0.0025 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 157 |
| 1 | Nonsteroidal Anti-inflammatory Drug [EPC] | 157 |
| 2 | Tumor Necrosis Factor Blocker [EPC] | 152 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 128 |
| 4 | Aminosalicylate [EPC] | 121 |
| 5 | Folate Analog Metabolic Inhibitor [EPC] | 119 |
| 6 | Interleukin-6 Receptor Antagonist [EPC] | 117 |
| 7 | Selective T Cell Costimulation Modulator [EPC] | 113 |
| 8 | Antirheumatic Agent [EPC] | 112 |
| 9 | Atypical Antipsychotic [EPC] | 94 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 2 | 0.0029 |
| 1 | Anthelmintic [EPC] | 8 | 0.0028 |
| 2 | Provitamin D2 Compound [EPC] | 75 | 0.0025 |
| 3 | CD52-directed Cytolytic Antibody [EPC] | 34 | 0.0018 |
| 4 | Aminosalicylate [EPC] | 121 | 0.0012 |
| 5 | Antirheumatic Agent [EPC] | 112 | 0.0011 |
| 6 | Plasma Volume Expander [EPC] | 3 | 0.0010 |
| 7 | Guanylate Cyclase-C Agonist [EPC] | 2 | 0.0010 |
| 8 | Interleukin-6 Receptor Antagonist [EPC] | 117 | 0.0008 |
| 9 | Insulin-like Growth Factor-1 Receptor Inhibitor [EPC] | 5 | 0.0008 |